If you have an On-X® Aortic Mechanical Heart Valve, you may be eligible to be enrolled in an exciting clinical study.
The PROACT Xa Clinical Trial is studying whether a different blood thinning medication – apixaban (marketed under the brand name ELIQUIS®) – will provide the same benefit for patients with an On-X Aortic Mechanical Heart Valve compared with warfarin (marketed under the brand name COUMADIN®).
Contact us to learn more about the PROACT Xa study, your potential eligibility for the study, and/or which hospitals and institutions are participating in the study.
Except as otherwise noted, all trademarks are owned by Artivion, Inc. or its subsidiaries. The On-X Aortic Valve is not currently approved by the FDA for use with apixaban or any other anticoagulation, except vitamin K antagonist. ELLIQUIS® is a registered trademark of the Bristol-Myers Squibb Company. Neither Artivion nor the PROACT Xa Trial are affiliated with, sponsored, or endorsed by the Bristol-Myers Squibb Company. Not all products and indications are available or approved in all markets. © 2022 Artivion, Inc. All rights reserved.